Jennison Associates
TVTX icon

Jennison Associates’s Travere Therapeutics TVTX Stock Holding History

Jennison Associates’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-256,335
Closed -$9.79M – 637
2025
Q4 		$9.79M Sell
256,335
-828,015
-76% -$26.9M 0.01% 393
2025
Q3 		$25.9M Buy
1,084,350
+312,828
+41% +$5.88M 0.02% 305
2025
Q2 		$11.4M Sell
771,522
-80,602
-9% -$1.34M 0.01% 370
2025
Q1 		$15.3M Buy
852,124
+35,725
+4% +$725K 0.01% 353
2024
Q4 		$14.2M Buy
+816,399
New +$14.4M 0.01% 369
2019
Q2 		– Sell
-590,390
Closed -$13.4M – 677
2019
Q1 		$13.4M Sell
590,390
-114
-0% -$2.52K 0.01% 409
2018
Q4 		$13.4M Sell
590,504
-203,815
-26% -$5.07M 0.01% 406
2018
Q3 		$22.8M Sell
794,319
-276,008
-26% -$7.89M 0.02% 377
2018
Q2 		$29.2M Buy
1,070,327
+14,166
+1% +$377K 0.03% 347
2018
Q1 		$23.6M Buy
1,056,161
+93,365
+10% +$2.22M 0.02% 370
2017
Q4 		$20.3M Sell
962,796
-432,665
-31% -$9.89M 0.02% 403
2017
Q3 		$34.7M Sell
1,395,461
-302,464
-18% -$6.66M 0.04% 322
2017
Q2 		$32.9M Sell
1,697,925
-140,872
-8% -$2.56M 0.03% 326
2017
Q1 		$33.9M Sell
1,838,797
-287,097
-14% -$5.62M 0.04% 334
2016
Q4 		$40.2M Buy
2,125,894
+2,407
+0.1% +$49.2K 0.04% 300
2016
Q3 		$47.5M Sell
2,123,487
-140,788
-6% -$2.68M 0.05% 286
2016
Q2 		$40.3M Sell
2,264,275
-833
-0% -$13.5K 0.04% 319
2016
Q1 		$30.9M Sell
2,265,108
-78,551
-3% -$1.19M 0.03% 356
2015
Q4 		$45.2M Buy
2,343,659
+66,299
+3% +$1.32M 0.04% 300
2015
Q3 		$46.1M Sell
2,277,360
-690,143
-23% -$20.4M 0.05% 314
2015
Q2 		$98.4M Sell
2,967,503
-276,384
-9% -$7.57M 0.09% 205
2015
Q1 		$77.7M Buy
3,243,887
+96,594
+3% +$1.47M 0.07% 250
2014
Q4 		$38.5M Sell
3,147,293
-54,650
-2% -$566K 0.04% 366
2014
Q3 		$28.9M Buy
3,201,943
+473
+0% +$5.57K 0.03% 407
2014
Q2 		$37.6M Buy
3,201,470
+1,231,651
+63% +$16.7M 0.03% 367
2014
Q1 		$41.9M Buy
+1,969,819
New +$30.3M 0.04% 352

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jennison Associates's TVTX Position: Q1 2026 in Review

Jennison Associates sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 256,335 shares — an estimated $9.79M sold.

Jennison Associates first reported a position in TVTX in Q1 2014 and held it in 26 quarters. The position peaked at $98.4M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Jennison Associates reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jennison Associates sold 256,335 Travere Therapeutics shares in Q1 2026, an estimated $9.79M.
  • Jennison Associates first reported a position in Travere Therapeutics in Q1 2014 and held it in 26 quarters.
  • Jennison Associates's Travere Therapeutics position peaked at $98.4M in Q2 2015.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.